



NASDAQ: GNPX

## CORPORATE FACT SHEET

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes.

Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options.

Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches.

The Company's lead product candidate, REQORSA® (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).

Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an adeno-associated virus (AAV) vector to deliver Pdx1 and MafA genes to the pancreas.

### GENERAL COMPANY INFORMATION

- Founded in 2009: Publicly traded company (NASDAQ: GNPX) since 2018
- Headquartered in Austin, Texas
- Team of executives and advisors with broad business experience in the biotech and pharmaceutical industries and research and clinical experience at preeminent medical and academic institutions around the world
- Advancing novel gene therapies for large markets and unmet need, in cancer and diabetes, with world-class academic partners and an expanding pipeline

### ONCOLOGY

- Non viral gene therapy platform
- Novel approach using systemic gene therapy replacing tumor suppressor genes for cancer in humans
- Two FDA Fast Track Designations
- Clinical achievement in Ph 1 and Ph 2 studies
- Two lung cancer trials currently enrolling
- Near term data readouts

### DIABETES

- Two drug candidates addressing both Type 1 and Type 2 diabetes with AAV gene therapy
- Novel infusion process delivers gene to pancreas
- Potential to stabilize glucose levels and reduce insulin requirements shown in Non-Human Primate studies
- Near term data readouts

Statements contained herein not historical in nature are "forward-looking statements" (FLS) within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties and actual results may differ materially from those expressed or implied by such FLS and include statements relating to effects of our product candidates, planned clinical trials and potential partnerships, all as more fully described in Genprex's SEC filings.

To learn more about us, please visit:

[GENPREX.COM](http://GENPREX.COM)

**PIONEERING GENE THERAPIES  
FOR LARGE PATIENT POPULATIONS**